August 29, 2025

Gastrointestinal Foreign Bodies: When to Use Computed Tomography Versus Radiograph

A physician-focused review of gastrointestinal foreign body ingestion is looking to guide triage and intervention.

Conexiant

August 28, 2025

First Generic GLP-1 for Weight Loss Approved

FDA approves Teva’s generic Saxenda (liraglutide) with adult and adolescent indications and a boxed thyroid tumor warning.

Conexiant

August 28, 2025

CD68/CD163 Mark Worse Outcomes in Skeletal Hodgkin Lymphoma, Study

Skeletal classic Hodgkin lymphoma shows a macrophage-rich, B-cell–poor microenvironment, with high CD68/CD163 linked to worse survival.

Conexiant

August 27, 2025

FDA Approves LP.8.1 COVID-19 Vaccines

LP.8.1-targeted COVID-19 vaccines for adults 65 and older and higher-risk patients were approved by the US Food and Drug Administration.

Conexiant

August 26, 2025

Can States Still Respond to Outbreaks?

Following court injunctions, some states and cities regained funding, while others experienced continued cancellations that affected immunization clinics, workforce capacity, and infectious-disease surveillance.

KFF Health News

August 25, 2025

What Does Xlear’s Lawsuit Mean for Physicians?

Xlear's xylitol maker sues the FTC to loosen evidence rules on health claims, signaling a deregulatory push that could reshape supplement marketing.

KFF Health News

August 19, 2025

AAP Vaccine Recommendations Veer From ACIP

AAP released 2025 evidence-based US childhood and adolescent immunization schedule with updates for RSV, influenza, COVID-19, HPV, and meningococcal vaccines.

Conexiant

August 19, 2025

‘Enough Is Enough’—But When?

How Bogalusa, Louisiana became a lens on the US gun violence epidemic—where race, poverty, policy, and profit converge and communities bear the cost.

KFF Health News

August 18, 2025

Early Risdiplam Use in Presymptomatic SMA Infants

Presymptomatic treatment with risdiplam was associated with improved motor development and survival without permanent ventilation in infants with spinal muscular atrophy (SMA), according to 24-month results from the phase 2 RAINBOWFISH trial published in the New England Journal of Medicine.

Conexiant